Jubilant Pharmova Q3 FY2024 Financial Results Presentation

Jubilant Pharmova's financial results presentation for Q3 FY2024 (quarter ended December 31, 2023). The company reported FY23 revenue of approximately Rs 6,300 Cr (~US$ 783 million) and operates as an integrated global pharmaceuticals and contract research organization with strengths in radiopharmaceuticals, allergy immunotherapy, CDMO sterile injectables, and drug discovery services.